Bladder Cancer - Results from #700

REVIEW UroToday

Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal. December 8, 2023

Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching? December 7, 2023

TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary? December 7, 2023

The bladder microbiota is not significantly altered by intravesical BCG therapy. December 6, 2023

Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study. December 6, 2023

Secondary Bladder Cancers Following Prostate Cancer Treatment Modalities - Expert Commentary December 5, 2023

US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma December 5, 2023

Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer. December 5, 2023

Framework for a living systematic review and meta-analysis for the surgical treatment of bladder cancer: introducing EVIglance to urology. December 5, 2023

Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer December 4, 2023

Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System. December 4, 2023

Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. December 4, 2023

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer December 1, 2023

Robot-assisted oncologic pelvic surgery with Hugo™ robot-assisted surgery system: A single-center experience. December 1, 2023

Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year. December 1, 2023

Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma. November 30, 2023

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. November 30, 2023

On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. November 29, 2023

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. November 29, 2023

Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort. November 29, 2023

Page 36 of 517